QS-21 structure/function studies: effect of acylation on adjuvant activity

被引：92

作者：

Liu, G ^{[1
]}

Anderson, C ^{[1
]}

Scaltreto, H ^{[1
]}

Barbon, J ^{[1
]}

Kensil, CR ^{[1
]}

机构：

[1] Antigen Inc, Framingham, MA 01702 USA

来源：

VACCINE | 2002年 / 20卷 / 21-22期

关键词：

adjuvant; QS-21; structure/function; DS-1; GPI-0100;

D O I：

10.1016/S0264-410X(02)00209-8

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

QS-21 is a natural saponin adjuvant derived from the tree Quillaia saponaria Molina. Previous studies over a limited dose range suggested the acylation is critical to adjuvant activity. In this study, we prepared DS-1 (deacylated QS-21) and RDS-1 (reacylated DS-1 with dodecylamine at a different site than QS-21) to determine the effect on a dose-response curve over a wider range in mice. DS-1 and RDS-1 induced IgG1 responses at higher doses compared to that induced by QS-21. DS-1 was inactive for inducing IgG2a or CTL responses at any doses. RDS-1 showed moderate IgG2a response at 240 mug, but did not show CTL response at any dose evaluated. (C) 2002 Elsevier Science Ltd. All rights reserved.

引用

页码：2808 / 2815

页数：8

共 18 条

[1] Oral QS-21 requires early IL-4 help for induction of mucosal and systemic immunity [J].

Boyaka, PN ;

Marinaro, M ;

Jackson, RJ ;

van Ginkel, FW ;

Cormet-Boyaka, E ;

Kirk, KL ;

Kensil, CR ;

McGhee, JR .

JOURNAL OF IMMUNOLOGY, 2001, 166 (04) :2283-2290

[2] ADJUVANT ACTIVITY OF QS-21 FOR EXPERIMENTAL ESCHERICHIA-COLI-018 POLYSACCHARIDE VACCINES [J].

COUGHLIN, RT ;

FATTOM, A ;

CHU, CY ;

WHITE, AC ;

WINSTON, S .

VACCINE, 1995, 13 (01) :17-21

[3] QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immmunization in humans [J].

Evans, TG ;

McElrath, MJ ;

Matthews, T ;

Montefiori, D ;

Weinhold, K ;

Wolff, M ;

Keefer, MC ;

Kallas, EG ;

Corey, L ;

Gorse, GJ ;

Belshe, R ;

Graham, BS ;

Spearman, PW ;

Schwartz, D ;

Mulligan, MJ ;

Goepfert, P ;

Fast, P ;

Berman, P ;

Powell, M ;

Francis, D .

VACCINE, 2001, 19 (15-16) :2080-2091

[4]

Kensil C R, 1998, Expert Opin Investig Drugs, V7, P1475, DOI 10.1517/13543784.7.9.1475

[5]

KENSIL CR, 1991, J IMMUNOL, V146, P431

[6]

Kensil CR, 1998, DEV BIOL STAND, V92, P41

[7]

Kensil CR, 1996, ADV EXP MED BIOL, V404, P165

[8]

KENSIL CR, 1993, VACCINE RES, V2, P273

[9]

KENSIL CR, 1992, VACCINES, V92, P35

[10]

Lewis JJ, 2000, INT J CANCER, V87, P391, DOI 10.1002/1097-0215(20000801)87:3<391::AID-IJC13>3.0.CO

← 1 2 →